Skip to main content
All lobbying filings

LABORATORY CORPORATION OF AMERICA HOLDINGS

Lobbying for LABORATORY CORPORATION OF AMERICA HOLDINGS

 Filing 3rd Quarter - Amendment
3rd Quarter (July 1 - Sep 30) 2025 · North Carolina · House · Senate · $260,000.00 expenses · posted Jan 13, 2026

Official filing document

 Bills named in this filing 8
  • HR 5269
    RESULTS Act
  • S 2761
    RESULTS Act
  • HR 1
    An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
  • HCONRES 14
    Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appro…
  • HR 3514
    Improving Seniors’ Timely Access to Care Act of 2025
  • S 1816
    Improving Seniors’ Timely Access to Care Act of 2025
  • S 2355
    Patients Deserve Price Tags Act
  • HR 5444
    Medical Laboratory Personnel Shortage Relief Act of 2025
 Lobbying activity 2
Health Issues

Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; Federal policy relating to oversight of laboratory-developed tests; Section 71120 of H.R. 1, An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14, provisions relating to modifying cost sharing requirements for certain expansion individuals under the Medicaid program; H.R. 3514/S.1816, the Improving Seniors Timely Access to Care Act, provisions relating to prior authorization of services to Medicare Advantage beneficiaries; S. 2355, the Patients Deserve Price Tags Act, provisions relating to lab test price transparency; H.R. 5444, the Medical Laboratory Personnel Shortage Relief Act, provisions relating to medical laboratory personnel eligibility for the National Health Service Corps and federal grants for lab personnel training; Federal policy relating to implementation of Medicare reimbursement cuts under the Statutory Pay-As-You-Go Act of 2010, Pub. L. 111-139; and Federal policy related to supply chain issues affecting pre-clinical biomedical research for drug development.

Taxation/Internal Revenue Code

Sections 70301, 70302, 70412(b), and 70603 of H.R. 1, An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14, provisions relating to extension of bonus depreciation under Internal Revenue Code Section 168(k), immediate deductibility of domestic research and development expenses under Internal Revenue Code Section 174, individual deductibility of employer-funded tuition assistance under Internal Revenue Code Section 127, and executive compensation under Internal Revenue Code Section 162(m), respectively; Title VII, Subtitle A, Chapter 3, Subchapter B of such Act, provisions relating to treatment of tax credits and reporting simplification under international tax law and guidance; and federal policy relating to income tax rates for corporations and income tax deductibility of corporate state and local taxes.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem